Ascendis Pharma A/S
TransCon hGH
Turner syndrome
Resolved
112days ago
Phase 2 readout · Mar 17, 2026
What's at stake
Phase 2 trial results for TransCon hGH in Turner syndrome are due Mar 17, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 15h ago
“On March 17, 2026, the Company announced positive Week 52 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. investigating the safety, tolerability, and efficacy of once-weekly TransCo”